|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,905.50 DKK | +1.28% |
|
-4.03% | -5.90% |
| 02-04 | Goldman Sachs Lowers Price Target for Genmab to 1,793 Danish Kroner (from 1,880), Reiterates Neutral - BN | FW |
| 02-04 | Fitch Highlights Genmab's Antibody Oncology Leadership in Final Rating | MT |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Net Income | 4.76B | 3.01B | 5.52B | 4.35B | 7.84B | |||||
Depreciation & Amortization - CF | 157M | 220M | 328M | 185M | 335M | |||||
Amortization of Goodwill and Intangible Assets - (CF) | 109M | 84M | 70M | 55M | 78M | |||||
Depreciation & Amortization, Total | 266M | 304M | 398M | 240M | 413M | |||||
(Gain) Loss From Sale Of Asset | - | - | - | - | - | |||||
(Gain) Loss on Sale of Investments - (CF) | -873M | 689M | 659M | -293M | -247M | |||||
Asset Writedown & Restructuring Costs | 29M | - | 38M | - | 115M | |||||
Stock-Based Compensation (CF) | 200M | 310M | 439M | 586M | 721M | |||||
Other Operating Activities, Total | 1.07B | -1.31B | -1.21B | 1.13B | -337M | |||||
Change In Accounts Receivable | 306M | -1.07B | -2.21B | 797M | -1.59B | |||||
Change In Inventories | - | - | - | -57M | -5M | |||||
Change In Accounts Payable | 168M | 304M | 283M | 622M | 857M | |||||
Change in Unearned Revenues | 513M | - | - | - | - | |||||
Change in Other Net Operating Assets | - | - | - | - | - | |||||
Cash from Operations | 6.43B | 2.23B | 3.91B | 7.38B | 7.77B | |||||
Capital Expenditure | -307M | -252M | -317M | -366M | -187M | |||||
Cash Acquisitions | - | - | - | - | -12.25B | |||||
Sale (Purchase) of Intangible assets | - | - | - | -10M | -117M | |||||
Investment in Marketable and Equity Securities, Total | -2.04B | -709M | -2.44B | -906M | 2.64B | |||||
Cash from Investing | -2.35B | -961M | -2.76B | -1.28B | -9.91B | |||||
Long-Term Debt Repaid, Total | -44M | -58M | -73M | -91M | -60M | |||||
Total Debt Repaid | -44M | -58M | -73M | -91M | -60M | |||||
Issuance of Common Stock | 140M | 135M | 280M | 152M | 129M | |||||
Repurchase of Common Stock | -25M | -497M | -996M | -667M | -3.99B | |||||
Other Financing Activities, Total | - | - | - | - | - | |||||
Cash from Financing | 71M | -420M | -789M | -606M | -3.92B | |||||
Foreign Exchange Rate Adjustments | -445M | 850M | 574M | -518M | 1.05B | |||||
Net Change in Cash | 3.71B | 1.7B | 936M | 4.97B | -5.01B | |||||
Supplemental Items | ||||||||||
Cash Interest Paid | 20M | 12M | 16M | 25M | 35M | |||||
Cash Income Tax Paid (Refund) | 1.48B | 742M | 1.58B | 1.07B | 343M | |||||
Levered Free Cash Flow | 4.69B | 1.85B | 2.09B | 5.29B | 6.25B | |||||
Unlevered Free Cash Flow | 4.7B | 1.86B | 2.1B | 5.31B | 6.33B | |||||
Change In Net Working Capital | -577M | 391M | 2.41B | -1.54B | -1.07B | |||||
Net Debt Issued / Repaid | -44M | -58M | -73M | -91M | -60M |
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















